Abstract
In chronic obstructive pulmonary disease (COPD), cognitive dysfunction - mainly of secondary memory, executive, and constructional abilities - is a marker of disease severity with important clinical and prognostic implications. It correlates with poor compliance with pharmacological therapy, and poor compliance, in turn, increases the cost/effectiveness ratio of home care programs. Executive dysfunction is associated with difficulty with inhaler devices and should be systematically evaluated before prescribing. Drawing impairment has been associated with mortality, although the underlying neurologic abnormalities (right insular damage with autonomic dysfunction or subcortical damage) remain to be defined. Depression is also negatively correlated with survival, besides being a risk factor for quitting respiratory rehabilitation. Cognitive dysfunction should always be considered among the systemic effects of COPD and be the object of systematic screening in COPD patients. Identifying cognitive impairment would prompt either interventions promoting the adherence to the therapy or further investigations to exclude respiratory (nocturnal or effort hypoxemia, coexistent obstructive sleep apnoea) or non respiratory (decompensated diabetes, hypoglycaemic crises, poorly controlled hypertension etc.) causes of cognitive dysfunction. Cognitive enhancing strategies deserve consideration in the framework of a comprehensive approach aimed at improving the health status of people with COPD.
Keywords: Cognitive impairment, depression, chronic obstructive pulmonary disease
Current Respiratory Medicine Reviews
Title: Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD
Volume: 3 Issue: 2
Author(s): Andrea Corsonello, Claudio Pedone and Raffaele Antonelli Incalzi
Affiliation:
Keywords: Cognitive impairment, depression, chronic obstructive pulmonary disease
Abstract: In chronic obstructive pulmonary disease (COPD), cognitive dysfunction - mainly of secondary memory, executive, and constructional abilities - is a marker of disease severity with important clinical and prognostic implications. It correlates with poor compliance with pharmacological therapy, and poor compliance, in turn, increases the cost/effectiveness ratio of home care programs. Executive dysfunction is associated with difficulty with inhaler devices and should be systematically evaluated before prescribing. Drawing impairment has been associated with mortality, although the underlying neurologic abnormalities (right insular damage with autonomic dysfunction or subcortical damage) remain to be defined. Depression is also negatively correlated with survival, besides being a risk factor for quitting respiratory rehabilitation. Cognitive dysfunction should always be considered among the systemic effects of COPD and be the object of systematic screening in COPD patients. Identifying cognitive impairment would prompt either interventions promoting the adherence to the therapy or further investigations to exclude respiratory (nocturnal or effort hypoxemia, coexistent obstructive sleep apnoea) or non respiratory (decompensated diabetes, hypoglycaemic crises, poorly controlled hypertension etc.) causes of cognitive dysfunction. Cognitive enhancing strategies deserve consideration in the framework of a comprehensive approach aimed at improving the health status of people with COPD.
Export Options
About this article
Cite this article as:
Corsonello Andrea, Pedone Claudio and Antonelli Incalzi Raffaele, Clinical and Prognostic Implications of Cognitive Dysfunction and Depression in COPD, Current Respiratory Medicine Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339807780599162
DOI https://dx.doi.org/10.2174/157339807780599162 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Application of Proteomics in Neurology
Current Proteomics Role of Nicotinic Acetylcholine Receptors in Cardiovascular Physiology and Pathophysiology: Current Trends and Perspectives
Current Vascular Pharmacology Pidotimod and Immunological Activation in Individuals Infected with HIV
Current HIV Research Editorial (Thematic Issue: Novel Data on the Pathogenesis of Atherosclerosis, Treatment Targets, and New Therapeutic Interventions in Lipid-Related Cardiovascular Risk Factors)
Current Pharmaceutical Design Soluble Epoxide Hydrolase Inhibitors and Cardiovascular Diseases
Current Vascular Pharmacology Ventricular Arrhythmias in Patients with Obstructive Sleep Apnea
Current Cardiology Reviews Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets New Insights into the Intracellular Mechanisms by Which PGI2 Analogues Elicit Vascular Relaxation: Cyclic AMP-Independent, Gs-Protein Mediated-Activation of MaxiK Channel
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl)- phenyl)-3-(2-(amino)pyridin-3-yl)ureas as Novel KDR Kinase Inhibitors
Medicinal Chemistry Oxygen Sensing in Health and Disease
Current Respiratory Medicine Reviews Sodium Intake as a Modulator of Kidney Function
Current Hypertension Reviews The Interactions Between Alzheimer’s Disease and Major Depression: Role of Ca<sup>2+</sup> Channel Blockers and Ca<sup>2+</sup>/cAMP Signalling
Current Drug Research Reviews Phytoestrogen Genistein and Its Pharmacological Interactions with Synthetic Endocrine-Active Compounds
Current Pharmaceutical Design Neuropeptides as Therapeutic Targets in Anxiety Disorders
Current Pharmaceutical Design Hemostatic Factors and the Metabolic Syndrome
Current Vascular Pharmacology Validation of Two High-Performance Liquid Chromatographic Methods for the Analysis of Nadolol and Propranolol Hydrochloride Following In Vitro Transdermal Diffusion Studies
Current Pharmaceutical Analysis Impact of Patient Knowledge of Hypertension Complications on Adherence to Antihypertensive Therapy
Current Hypertension Reviews Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan
Current Bioactive Compounds Neuroinflammatory Markers in Spontaneously Hypertensive Rat Brain: An Immunohistochemical Study
CNS & Neurological Disorders - Drug Targets Impact of Oral 1,25-Dihydroxy Vitamin D (Calcitriol) Replacement Therapy on Coronary Artery Risk Factors in Type 2 Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets